-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
HCA Healthcare delivered Q1 2026 EPS of $7.15, in line with consensus and up 10.9% Y/Y, while revenue of $19.109B grew 4.3% and beat the $19.07B consensus estimate. Same-facility admissions rose 1.3%, though surgical volumes declined with inpatient and outpatient surgeries down 0.3% and 1.7%, respectively, reflecting softness in elective procedures and seasonal headwinds. Strong share repurchase activity of $1.571B during the quarter supported EPS growth despite volume pressures. Management reaffirmed 2026 guidance ranges, indicating confidence in navigating policy headwinds. Adjusted EBITDA margin compressed 50 bps to 19.9% due to challenging volumes and inflationary cost pressures, though operating cash flow surged 22% to $2.014B. We view the continued strong cash generation and $9.179B remaining share repurchase authorization as supportive of capital returns despite headwinds from ACA enhanced premium tax credit expirations and OBBBA Medicaid funding cuts.